No Data
Viking Therapeutics Analyst Ratings
B.Riley Financial Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $109
Viking Therapeutics: Strong Potential in Obesity and Type 2 Diabetes Market With Innovative VK2735 Program
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
Viking Therapeutics Is More Than Just a Weight-loss Stock, and That's Drawing Cheers
Express News | Viking Therapeutics Shares Rise 4.6% Premarket After Co Presents Detailed Mid-Stage Data for Experimental Liver Disease Drug
No Data
No Data
HugoV : Yes on our way to 90